Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review
- 18 March 2019
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (8) , 1316-1328
Abstract
Background and Aim: Gastroesophageal reflux disease (GERD) is a common disease caused by reflux of gastric contents to the esophagus. Proton‐pump inhibitors (PPIs) are recommended as a first‐line therapy to treat GERD. Recently, a new potassium‐competitive acid blocker, vonoprazan, was launched in Japan. We aimed to evaluate the comparative efficacy of vonoprazan and other PPIs in healing GERD.Methods: We used MEDLINE and the Cochrane Central Register of Controlled Trials to search the literature. Double‐blind randomized controlled trials for PPIs and/or vonoprazan that were published in English or Japanese and assessed healing effects in adult GERD patients were included. To estimate the comparative efficacy of treatments, we performed a Bayesian network meta‐analysis to assess the consistency assumption.Results: Of 4001 articles identified in the database, 42 studies were eligible. One study was hand‐searched and added to the analysis. For the main analysis of healing effects at 8 weeks, odds ratios (ORs) of vonoprazan (20 mg daily) to esomeprazole (20 mg), rabeprazole (20 mg), lansoprazole (30 mg), and omeprazole (20 mg) were 2.29 (95% credible interval, 0.79–7.06), 3.94 (1.15–14.03), 2.40 (0.90–6.77), and 2.71 (0.98–7.90), respectively. Subgroup analysis for patients with severe esophagitis at baseline showed significantly higher ORs for vonoprazan versus most of the comparator PPIs.Conclusions: This analysis shows that the GERD healing effect of vonoprazan is higher than that of rabeprazole (20 mg) but not higher than other PPIs. Subgroup analysis indicated that vonoprazan is more effective than most PPIs for patients with severe erosive esophagitis.Keywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 67 references indexed in Scilit:
- Evidence Synthesis for Decision Making 4Medical Decision Making, 2013
- Efficacy of S-Pantoprazole 20 mg Compared with Pantoprazole 40 mg in the Treatment of Reflux Esophagitis: A Randomized, Double-Blind Comparative TrialDigestive Diseases and Sciences, 2012
- Systematic review of the epidemiology of gastroesophageal reflux disease in JapanJournal of Gastroenterology, 2011
- Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studiesAlimentary Pharmacology & Therapeutics, 2010
- A Multicenter, Randomized, Double-Blind, 8-Week Comparative Trial of Standard Doses of Esomeprazole (40 mg) and Omeprazole (20 mg) for the Treatment of Erosive EsophagitisDigestive Diseases and Sciences, 2006
- Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitisAlimentary Pharmacology & Therapeutics, 2005
- The Impact of Treatment for Gastro-Oesophageal Reflux Disease on Health-Related Quality of LifePharmacoEconomics, 2003
- Natural history of nonerosive reflux disease: Is all gastroesophageal reflux disease the same? What is the evidence?Gastroenterology Clinics of North America, 2002
- Bayesian Measures of Model Complexity and FitJournal of the Royal Statistical Society Series B: Statistical Methodology, 2002
- Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?Journal of Gastroenterology, 1999